Project Grant R01HL182700
Award Date 8/24/26
Completion Date 5/31/29
Dollars Obligated $355K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $717,680 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune epithelial niche mechanisms underlying post-viral lung fibrosis. The research examines how anti-viral CD8+ T cell immunity, specifically interferon-gamma signaling and macrophage-derived interleukin-1 beta secretion, impairs alveolar epithelial repair following severe respiratory viral infections. The...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $1,579,157 on June 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate conformational changes in fibronectin as a therapeutic target in idiopathic pulmonary fibrosis. The research examines stretch-dependent conformational changes in fibronectin within active fibrogenic regions of lung tissue from IPF patients, tests the molecular mechanisms by which stretch-induced fibronectin...
- The National Heart, Lung, and Blood Institute awarded Duke University $215,504 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025, to fund research on epithelial cell-mediated fibroblast activation through CTHRC1-TGFB signaling in fibrotic lung diseases. The research investigates mechanisms of fibroblast activation in bronchiolitis obliterans and idiopathic pulmonary fibrosis. Aim 1 evaluates airway epithelial cell-fibroblast interactions contributing to...
- The National Heart, Lung, and Blood Institute (NHLBI) of the Department of Health and Human Services awarded $1,545,864 to the University of Pittsburgh on August 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund Project Grant R01HL187347, an investigation into immune-mediated lung repair following early life respiratory viral infection. The research defines mechanisms of viral lower respiratory tract infection (LRTI)–driven lung damage and repair in neonates, with...
- Virginia Commonwealth University was awarded a $210,611.86 Project Grant from the Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute on January 31, 2021. The grant supports research under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate "Tissue Stiffness Promotes Pro-Fibrotic Metabolic Dysregulation in Lung Fibrosis." This two-year project aims to foster basic research on the relationship between tissue...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $1,619,582 to the University of Virginia on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cardio-splenic axis in acute myocardial infarction and post-MI heart failure. The project examines the immunopathological mechanisms by which plasmacytoid dendritic cells orchestrate post-MI inflammation and cardiac dysfunction. The research team...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Virginia $385,176 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a K23 career development award for Dr. Lindsay Somerville to investigate immune mechanisms driving recurrent pulmonary exacerbations in cystic fibrosis patients who do not fully respond to highly effective modulator therapy. Dr. Somerville, Assistant Professor of Pulmonary and Critical Care Medicine and...
- The National Heart, Lung, and Blood Institute awarded The Trustees Of The University Of Pennsylvania $1,624,110 on June 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of lung repair and regeneration following acute injury. The project examines dysplastic versus euplastic repair pathways in lung tissue. The research addresses how basal stem cells migrate into the alveolar niche after injury, displacing AT2 progenitor cells and creating an...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded National Jewish Health $249,000 on July 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate rare airway cell function in post-viral chronic inflammation. The research examines the role of microfold (M) cells in the post-influenza lung, particularly their contribution to secondary bacterial infection susceptibility and host protection. Using single-nucleus transcriptomic and...